Alopecia Treatment Data Have Shown Hair Regrowth
New clinical trial results indicate that rezpegaldesleukin may support hair regrowth in patients with alopecia areata.
Updated on Oct. 13, 2026 in Allergies
Live Poll
Would you be willing to try an experimental hair regrowth treatment before long-term data exists?
Researchers have presented 52-week clinical trial data for the drug rezpegaldesleukin, which demonstrated success in treating alopecia areata. Participants in the study showed consistent hair regrowth over the course of the trial period.
Why it matters
The drug utilizes a regulatory T cell-inducing interleukin-2 receptor agonist to address the underlying causes of hair loss. These findings provide insight into a potential new therapeutic path for those affected by the condition.
In the 92-person REZOLVE-AA phase 2b trial, 35.0% of the 24 µg/kg dosage group and 30.2% of the 18 µg/kg group achieved a SALT score of 30 or lower by week 52. These figures are compared against an 8.4% success rate in the placebo group.
The players
EADV Congress
The European Academy of Dermatology and Venereology Congress is a major annual scientific meeting for dermatologists.
The details
Patients with a SALT score higher than 20 at week 36 participated in a blinded 16-week treatment extension, with 94% of that cohort completing the period. The medication is administered subcutaneously every 2 weeks, and no increased risk of malignancy, conjunctivitis, or oral herpes has been observed in over 1,000 treated patients.
Timeline
September 30-October 3, 2026: Results were presented at the EADV Congress in Vienna.
End of 2026: The phase 3 clinical program is scheduled to begin.
The Big Picture
The upcoming phase 3 clinical program for rezpegaldesleukin builds on the positive efficacy and safety data observed in the phase 2b trial. These results extend the scientific validation of using interleukin-2 receptor agonists to address autoimmune-related hair loss.
The positive data suggests a potential future treatment option for individuals struggling with alopecia areata. Patients should note that these findings are based on a clinical trial and have not yet been peer-reviewed or approved for general medical use.
The takeaway
Advancements in immune-modulating treatments offer hope for those managing chronic autoimmune conditions like alopecia areata. Patients are encouraged to consult with specialists to stay updated on emerging clinical trial outcomes and future treatment availability.
What happens next
The phase 3 clinical program for rezpegaldesleukin is scheduled to commence at the end of 2026.
Further reading
Learn more about evolving research in Allergies.
More information
For more information, review the Clinical trial study details on the official registry.
Source note: This article includes information reported by Hcplive.
Live Poll
Would you be willing to try an experimental hair regrowth treatment before long-term data exists?
